TLR3 and COVID-19: Additionally, a clinical study to evaluate the inhibition of TLR3-mediated inflammatory responses by Famotidine [87] to improve outcomes in patients with COVID-19 has been conducted (NCT04389567, NCT04504240, NCT04724720, NCT04370262) [88,89].